Biotech, acquisitions, deals
TheraGenetics Bought by Avacta
Luke Timmerman 1/29/09
TheraGenetics, a Cambridge, MA and London-based diagnostics company, said today it agreed to be acquired by UK-based Avacta Group for an undisclosed amount of cash and stock. TheraGenetics is developing diagnostic tests to see how individual patients might respond to drugs for schizophrenia, depression, bipolar disorder, Alzheimer’s disease and attention deficit hyperactivity disorder.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
2/2/09 1:50 pm
[...] Theragenetics is another not-so-well know company that develops diagnostic tests for various CNS diseases. The company announced back in January that contract service provider Avacta would be acquiring them for $2.9M. Peanuts. [Xconomy] [...]